Ginsenoside Rg1 treatment at 5, 10, and 20 mg/kg markedly decreased α-SMA and vimentin expressions and restored E-cad level in a dose-dependent manner (P < 0.05 versus COPD group). The gene discussed is VIM; the disease is chronic obstructive pulmonary disease.